SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report, dated September 5, 2025, covers the results of a Special Meeting of Stockholders held by BioSig Technologies, Inc. The filing details the approval of several corporate governance and capital structure proposals, as well as the adjournment of a critical acquisition-related proposal pending regulatory approval.
Key Financial Metrics and Capital Structure
The filing does not provide specific revenue, profit, cash flow, or debt metrics. However, it reports significant changes to the company's authorized capital:
- Authorized Common Stock: Increased from 200,000,000 to 500,000,000 shares via the Ninth Amendment to the Certificate of Incorporation.
- Incentive Plan Shares: The 2023 Long-Term Incentive Plan was amended to increase authorized shares by 10,359,211, bringing the total to 14,735,806 shares.
- Voting Power: As of the July 30, 2025 record date, there were 31,326,659 votes from common stockholders and 354,818 votes from Series C Convertible Preferred Stock holders.
Material Changes and Voting Results
Stockholders approved five of six proposals at the Special Meeting. The results were as follows:
- Proposal 2 (Convertible Debenture Issuance): Approved. 16,200,304 votes For vs. 254,639 Against.
- Proposal 3 (Incentive Plan Amendment): Approved. 15,434,968 votes For vs. 1,043,333 Against.
- Proposal 4 (SEPA Share Issuance): Approved. 16,239,812 votes For vs. 239,197 Against.
- Proposal 5 (Authorized Shares Increase): Approved. 19,620,210 votes For vs. 339,524 Against.
- Proposal 6 (Classified Board): Approved. 15,424,979 votes For vs. 1,009,783 Against.
Outlook, Risks, and Unusual Items
Adjourned Proposal 1 (Streamex Acquisition): The proposal to approve the issuance of approximately 109,070,079 shares of common stock and one share of Super Voting Preferred Stock in connection with the acquisition of Streamex Exchange Corporation was not voted upon. The meeting was adjourned pending Nasdaq approval. The reconvened meeting is scheduled for September 26, 2025.
Corporate Governance Change: The company will now operate with a classified board of directors, featuring three classes with staggered three-year terms.
Investor Verification Checklist
- Verify the status of Nasdaq approval for Proposal 1 (Streamex Acquisition) prior to the September 26, 2025 reconvened meeting.
- Review the definitive proxy statement (filed August 4, 2025, with amendments) for full details on the Streamex acquisition terms and the convertible debentures to Yorkville.
- Assess the dilution impact of the approved 109+ million share issuance pending the final vote on Proposal 1.
- Confirm the effective date and terms of the Ninth Certificate of Amendment filed with the Delaware Secretary of State.